EASL-EASD-EASO Guidelines Redefine MASLD Care With Resmetirom Entry

The first joint hepatology, diabetology, and obesity guideline under the new MASLD nomenclature elevates incretin therapies and introduces resmetirom as the first approved MASH-targeted pharmacotherapy.

EASL-EASD-EASO MASLD GuidelineEuropean Association for the Study of the Livermetabolic dysfunction-associated steatotic liver diseaseresmetiromGLP-1 receptor agonistsincretin therapies Gastroenterology / Hepatology

Background Information

New guidelines transform MASLD management with non-invasive testing and targeted therapies.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major health issue linked to cardiometabolic risks and serious liver complications. Guidelines recommend a stepwise approach with non-invasive tests for diagnosing liver fibrosis and emphasize lifestyle changes and selected pharmacotherapies. Non-invasive strategies and clear guidelines could improve diagnosis and management, impacting pharmacists involved in metabolic and liver disease care. MASLD management requires stepwise diagnosis and integration of lifestyle and pharmacologic therapies.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)

Citation: European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of hepatology. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →